La cadena de opciones muestra datos clave de las opciones de acciones de Silvergate Capital a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Silvergate Capital..

Silvergate Capital (OTC:SICLQ) Bolsa, Cadena de Opciones

Silvergate Capital Corp is a provider of various financial infrastructure solutions and services. Its solutions and service offerings include Silvergate Exchange Network, Cash Management Solutions and Deposit Account Services. Its customers include U.S. exchanges and global investors in the digital currency industry. The company also provides financial services that include commercial banking, business lending, commercial and residential real estate lending, and mortgage warehouse lending.

5.375% PRF PERPETUAL USD 25 - Ser A 1/40th Int

SILVERGATE CPTL D/S PFD A by Silvergate Capital Corporation

Silvergate Capital Corp

DATS

DatChat's Dragon Interact Subsidiary Acquires RPM Interactive In Consideration For The Issuance Of 3.5M Shares Of Common Stock

<ul>
<li>Revenue: $24.9 billion to $25.5 billion</li>
<li>GAAP EPS: $1.77 to $1.89</li>
<li>Adjusted EPS: $2.39 to $2.51</li>
</ul>

News

Guidance

FLEX

Flex Revised FY25 Outlook For Revenues To $24.9B-$25.5B (From $25.4B-$26.4B) Vs. $25.78B Estimate, Adjusted EPS To $2.39-$2.51 (From $2.30-$2.50) Vs. $2.41 Estimate

B of A Securities analyst Julien Dumoulin-Smith maintains First Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) with a Buy and lowers the price target from $321 to $269.

Price Target

Analyst Ratings

FSLR

B of A Securities Maintains Buy on First Solar, Lowers Price Target to $269

Needham analyst James Ricchiuti maintains CECO Environmental (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CECO#NASDAQ">CECO</a>) with a Buy and lowers the price target from $35 to $33.

CECO

Needham Maintains Buy on CECO Environmental, Lowers Price Target to $33

Avnet Sees Q2 Sales Of $5.40B-$5.70B Vs. $5.5B Estimate; Projects Diluted EPS Of $0.80-$0.90 Vs. $1.01 Estimate

Barclays analyst Ross Sandler maintains Alphabet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) with a Overweight and raises the price target from $200 to $220.

GOOG

Barclays Maintains Overweight on Alphabet, Raises Price Target to $220

GDEV Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDEV#NASDAQ">GDEV</a>), an international gaming and entertainment company ("GDEV" or the "Company"), announces changes to its Board of Directors and executive leadership team as part of its ongoing strategy to enhance operational efficiency and support its global growth ambitions.
Olga Loskutova, who has served as an Independent Director on GDEV's Board since 2022, will be stepping down from her position on the Board of Directors to assume the role of Chief Operating Officer (COO) of GDEV. Olga brings with her a wealth of experience in global business and general management, positioning her to provide management, leadership, and vision to guide GDEV Inc. towards meeting both its short-term and long-term strategic goals.
Following Olga's transition, GDEV's Board will consist of six members, with four remaining independent directors. In addition, Olga's seat on the Nomination and Compensation Committee, on which she previously served, has been assumed by current independent director Tal Shoham.

Management

GDEV

GDEV Announces Olga Loskutova Will Be Stepping Down From Her Position On The Board Of Directors To Assume The Role Of Chief Operating Officer

WIIM

THRY

Thryv Holdings shares are trading lower after the company reported preliminary Q3 results. Also, the company announced a $75 million public offering and announced the proposed acquisition of Keap.

Biotech

General

MLYS

Mineralys Therapeutics Completes Early Enrollment In Second Pivotal Trial For Lorundrostat In Hypertension; Topline Data Expected In Mid First Half Of 2025, With Virtual KOL Event To Discuss Unmet Need And Clinical Program

Gates Industrial Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GTES#NYSE">GTES</a>) raises FY2024 Adj EPS guidance from $1.29-1.35 to $1.33-1.37 vs $1.31 analyst estimate. Narrows FY2024 sales outlook from $3.44 billion-3.51 billion to $3.44 billion-3.47 billion vs $3.41 billion estimate.

GTES

Gates Industrial Corp Raises FY2024 Adj EPS Guidance from $1.29-1.35 to $1.33-1.37 vs $1.31 Est; Core Sales growth of -4 to -3%.

B of A Securities analyst Justin Post maintains Reddit (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) with a Neutral and raises the price target from $84 to $99.

RDDT

B of A Securities Maintains Neutral on Reddit, Raises Price Target to $99

Biomarker cohort for delpacibart braxlosiran (del-brax), the first potential therapy to target DUX4, is measuring changes in DUX4 regulated biomarkers; del-brax 2 mg/kg will be administered every six weeks
Enrollment in the del-brax biomarker cohort expected to be completed in 1H 2025; on track to initiate del-brax functional cohort in 1H 2025
In previously reported initial data, del-brax 2 mg/kg every six weeks showed unprecedented and consistent reductions of DUX4 regulated genes, significant decreases in novel circulating biomarker and creatine kinase, and trends of functional improvement at the four-month timepoint
SAN DIEGO, Oct. 30, 2024 /PRNewswire/ --&nbsp;Avidity Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs&#x2122;), today announced the initiation of a biomarker cohort in the Phase 1/2&nbsp; FORTITUDE&#x2122; trial of delpacibart braxlosiran (del-brax/AOC 1020) in people living with facioscapulohumeral muscular dystrophy (FSHD). Avidity is pursuing a potential accelerated approval path for del-brax and expects enrollment in the biomarker cohort to be completed in the first half of 2025. Avidity also remains on track to initiate a functional cohort in the first half of 2025. In addition, enrollment of the FORTITUDE Open-label Extension study (OLE) is ongoing.

Avidity Biosciences Pursues Potential Accelerated Approval Path With Initiation Of Biomarker Cohort In FORTITUDE Trial For Delpacibart Braxlosiran In People Living With Facioscapulohumeral Muscular Dystrophy

Flex Sees Q3 Revenues Of $6.0B-$6.4B Vs. $6.5B Estimate, Adjusted EPS Of $0.60-$0.66 Vs. $0.56 Estimate

Trinity Cap (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIN#NASDAQ">TRIN</a>) reported quarterly earnings of $0.52 per share which met the analyst consensus estimate. This is a 5.45 percent decrease over earnings of $0.55 per share from the same period last year. The company reported quarterly sales of $61.77 million which beat the analyst consensus estimate of $55.53 million by 11.23 percent. This is a 33.01 percent increase over sales of $46.44 million the same period last year.

Earnings

Earnings Beats

TRIN

Trinity Cap Q3 EPS $0.52, Inline, Sales $61.77M Beat $55.53M Estimate

Results indicated PMN310 was generally well-tolerated and monthly dosing can provide CSF levels adequate for target engagement
Initiation of Phase 1b clinical trial in Alzheimer's disease patients planned for year-end 2024
&nbsp;
CAMBRIDGE, Massachusetts and TORONTO, Ontario, Oct. 30, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMN#NASDAQ">PMN</a>), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today presented positive results from all five cohorts from the Phase 1a, single ascending dose clinical trial of its lead product candidate, PMN310, at the 17th Clinical Trials on Alzheimer's Disease (CTAD) Conference taking place from October 29 – November 1, 2024 in Madrid, Spain.
PMN310 is an investigational humanized monoclonal antibody (mAb) designed and developed to selectively target soluble amyloid beta oligomers (AβOs), which ProMIS believes to be the most toxic and pathogenic form of Aβ, relative to Aβ monomers and amyloid plaques.

ProMIS Neurosciences Presents Data From PMN310 Phase1a Clinical Trial At The 17th Clinical Trials On Alzheimer's Disease Conference; Results Indicated PMN310 Was Generally Well-Tolerated And Monthly Dosing Can Provide CSF Levels Adequate For Target Engagement

B of A Securities analyst Tal Liani downgrades Check Point Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHKP#NASDAQ">CHKP</a>) from Buy to Neutral and lowers the price target from $205 to $195.

Downgrades

CHKP

B of A Securities Downgrades Check Point Software to Neutral, Lowers Price Target to $195

Abits Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABTS#NASDAQ">ABTS</a>) reported $1.26 million in sales this quarter.

ABTS

Abits Group Q3 Sales $1.26M

PSNY

TSLA

Polestar Expands Charging Access With 17,800 Tesla Superchargers In North America And Over 850,000 Charging Points Across Europe, Enhancing Global EV Charging Network

WING

Wingstop Is Reiterates Guidance Of Approximately 20% Domestic Same Store Sales Growth For Fiscal Year 2024

<h3>Gainers</h3>
<ul>
<li>Haoxi Health Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAO#NASDAQ">HAO</a>) shares rose 53.7% to $0.28 during Wednesday's pre-market session. The company's market cap stands at $10.0 million. As per the press release, FY earnings came out yesterday. </li>
<li>Reddit (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) shares increased by 20.25% to $98.3. The company's market cap stands at $16.3 billion. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Global Mofy AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GMM#NASDAQ">GMM</a>) shares moved upwards by 17.45% to $0.43. The market value of their outstanding shares is at $14.5 million. </li>
<li>Snap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) shares moved upwards by 10.83% to $12.07. The market value of their outstanding shares is at $20.0 billion. As per the press release, Q3 earnings came out yesterday. </li>
<li>LQR House (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LQR#NASDAQ">LQR</a>) shares increased by 8.52% to $0.8. The company's market cap stands at $4.3 million. </li>
<li>Anghami (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGH#NASDAQ">ANGH</a>) shares rose 8.21% to $0.82. The market value of their outstanding shares is at $54.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Thryv Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRY#NASDAQ">THRY</a>) stock decreased by 13.8% to $15.8 during Wednesday's pre-market session. The company's market cap stands at $573.5 million. </li>
<li>Criteo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRTO#NASDAQ">CRTO</a>) shares fell 8.35% to $39.1. The company's market cap stands at $2.1 billion. The company's, Q3 earnings came out today. </li>
<li>ZW Data Action Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNET#NASDAQ">CNET</a>) shares declined by 6.71% to $2.06. The company's market cap stands at $4.4 million. </li>
<li>Trump Media &amp; Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) stock decreased by 6.12% to $48.36. The market value of their outstanding shares is at $9.6 billion. </li>
<li>Blue Hat Interactive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BHAT#NASDAQ">BHAT</a>) shares fell 5.67% to $0.28. The market value of their outstanding shares is at $16.5 million. </li>
<li>Leafly Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFLY#NASDAQ">LFLY</a>) shares declined by 5.56% to $1.7. The market value of their outstanding shares is at $4.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-communication-services-stocks/" title="www.benzinga.com/money/best-communication-services-stocks/">www.benzinga.com/money/best-communication-services-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

Silvergate Capital

Silvergate Capital (SICLQ) Opciones

Loading...

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL